BiondVax Pharmaceuticals Ltd. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 8 of 8 Posts
BiondVax Receives €8m From The European Investment Bank
Article By: PR Newswire Tuesday, October 23, 2018 1:54 AM EDT
The money from the EIB is in support of manufacturing facility and ongoing Phase 3 clinical trial.
In this article: BVXV
Read
BiondVax Appoints CRO To Conduct Pivotal Clinical Efficacy Phase 3 Trial Of Its Novel Universal Flu Vaccine Candidate
Article By: PR Newswire Tuesday, March 13, 2018 9:27 AM EDT
BiondVax Pharmaceuticals developer of the Universal Flu Vaccine candidate M-001, announced today the signing of a Master Service Agreement with a contract research organization to conduct the first pivotal, clinical efficacy, Phase 3 trial of M-001.
In this article: BVXV
Read
BiondVax And European UNISEC Consortium To Host Universal Flu Vaccine Conference
Article By: PR Newswire Thursday, February 8, 2018 10:40 AM EDT
BiondVax Pharmaceuticals Ltd. developer of a Universal Flu Vaccine candidate currently in preparation for a Phase 3 clinical trial, and the European UNISEC consortium announced today they will co-host the Annual UNISEC Consortium Meeting.
In this article: BVXV
Read
BiondVax Universal Flu Vaccine Patent Granted In India
Article By: PR Newswire Tuesday, January 2, 2018 10:05 AM EDT
With a population of over 1.3 billion people, and high population density in some of the major cities, India is an important potential market for BiondVax and a universal flu vaccine may significantly improve public health.
In this article: BVXV
Read
BiondVax Plans Phase 3 Clinical Trial Following Receipt Of Scientific Advice From The European Medicines Agency (EMA)
Article By: PR Newswire Wednesday, December 27, 2017 12:00 PM EDT
BiondVax Pharmaceuticals Ltd. announced today that the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) reviewed BiondVax's Phase 3 trial plan, provided advice, and allowed the Company to proceed.
In this article: BVXV
Read
BiondVax Provides Third Quarter 2017 Financial Results And Update
Article By: PR Newswire Tuesday, November 28, 2017 11:16 AM EDT
BiondVax Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced its financial results for the quarter ended September 30, 2017.
In this article: BVXV
Read
BiondVax And NIH Sign Clinical Trial Agreement For A Phase 2 Trial In The U.S. With BiondVax's Universal Flu Vaccine
Article By: PR Newswire Monday, November 20, 2017 1:09 PM EDT
BiondVax Pharmaceuticals Ltd. today announced the signing of the clinical trial agreement (CTA) for a Phase 2 clinical trial with the National Institute of Allergy and Infectious Diseases (NIAID) of the U.S. National Institutes of Health (NIH).
In this article: BVXV
Read
Premarket Biotech Digest 2016-03-31: VRX Debt, OPK RAYALDEE NDA, ICPT Presentation
Article By: KKD Healthcare Analytics Thursday, March 31, 2016 9:10 AM EDT
Daily premarket biotech digest for March 31, 2016.
In this article: AGN, JNJ, OPK, PFE, VRX, ACAD, ANAC, ICPT, SRPT, GLMD, CTRV, BVXV, TKPYY
Read
1 to 8 of 8 Posts